Skip to main content
NVDA+0.76%AAPL-1.08%GOOGL-1.50%MSFT-1.31%AMZN-1.51%TSM-0.50%SPCX-1.67%META+0.12%AVGO-0.65%TSLA-0.02%SKHY+1.69%BRK-B+0.05%LLY+0.38%MU+1.58%JPM-0.59%WMT-0.21%AMD+2.95%V-0.51%XOM+1.71%JNJ-1.20%ASMLa-0.52%0700.HK+1.90%MA-1.14%INTC+2.01%ABBV-0.51%1398.HK-2.09%CSCO+0.92%CVX+1.52%BAC+0.09%ORCL-1.88%COST-0.98%KO-1.05%CAT-0.39%DELL+4.16%HSBA.L-0.77%0005.HK-3.21%UNH-1.58%PG-0.14%LRCX-1.21%AP2d-1.57%AMAT-0.50%NFLX-3.41%GE-1.97%MS-1.82%1816.HK-0.46%3988.HK-2.13%0857.HK+0.60%HD-1.15%PM-1.35%0939.HK-2.83%NZDUSD-0.99%USDJPY+0.87%GBPNZD+0.77%NZDCHF-0.71%USDTHB+0.70%NZDCAD-0.68%CHFJPY+0.67%GBPJPY+0.61%AUDUSD-0.60%EURNZD+0.57%CADJPY+0.56%EURUSD-0.43%EURJPY+0.42%GBPTRY+0.41%AUDNZD+0.40%NZDMXN-0.39%GBPAUD+0.34%PLNJPY+0.33%GBPHKD+0.32%USDCAD+0.31%AUDCHF-0.29%AUDJPY+0.29%USDCHF+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCAD-0.27%USDTRY+0.25%NZDSGD-0.24%GBPUSD-0.23%SGDJPY+0.21%EURAUD+0.18%EURGBP-0.17%AUDDKK-0.16%USDILS+0.16%EURSGD+0.16%USDSGD+0.16%EURSEK+0.16%USDSEK+0.15%EURCAD-0.14%EURCHF-0.12%NZDJPY-0.12%EURCZK+0.11%CHFNOK-0.10%GBPSGD+0.10%GBPZAR-0.10%AUDNOK-0.08%GBPCAD+0.08%USDNOK+0.08%EURNOK+0.07%USDCNH+0.07%USDZAR-0.06%EURZAR-0.05%EURCNH+0.05%USDCOP-0.04%CADCHF-0.04%GBPCHF+0.03%EURPLN+0.03%USDPLN+0.03%CHFSGD-0.03%CHFSEK-0.02%USDHKD+0.02%USDMXN+0.01%EURHKD+0.01%USDDKK-0.01%EURDKK-0.01%AUDSGD0.00%USOIL+1.87%UKOIL+1.20%XNGUSD+0.93%SUGAR-0.88%COFFEE-0.80%W1+0.77%S1+0.61%C1+0.59%HG1+0.52%XPTUSD+0.51%GAGUSD+0.36%XAGUSD+0.36%BTCUSD-2.30%ETHUSD-3.00%USDTUSD-0.03%XRPUSD-1.12%SOLUSD-2.44%TRXUSDT-0.15%ZECUSDT-3.23%DOGEUSD-1.15%XMRUSDT+0.88%LINKUSD-1.80%XLMUSD+2.00%BCHUSDT-0.09%UNIUSD-3.07%LTCUSD-1.65%HBARUSDT+0.70%TONUSD+26.79%SUIUSD-1.69%TAOUSDT-3.21%AAVEUSD-1.00%DOTUSDT-1.91%ICPUSDT-6.96%ONDOUSDT-2.67%WLDUSDT-1.03%ARBUSDT+3.90%ATOMUSDT-1.35%JUPUSDT-3.88%INJUSDT-6.42%STXUSDT-1.97%FETUSDT-3.34%PYTHUSDT-3.63%TIAUSDT-4.18%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-1.70%GRTUSDT-3.39%WIFUSDT-4.27%POLUSDT+0.38%IOTAUSDT-4.18%AXSUSDT-2.99%FARTCOINUSDT-0.77%EOSUSDT-3.12%DYDXUSDT-5.44%ORDIUSDT-1.04%GALAUSDT-0.88%NOTUSDT-0.18%RONINUSDT-4.03%NVDA+0.76%AAPL-1.08%GOOGL-1.50%MSFT-1.31%AMZN-1.51%TSM-0.50%SPCX-1.67%META+0.12%AVGO-0.65%TSLA-0.02%SKHY+1.69%BRK-B+0.05%LLY+0.38%MU+1.58%JPM-0.59%WMT-0.21%AMD+2.95%V-0.51%XOM+1.71%JNJ-1.20%ASMLa-0.52%0700.HK+1.90%MA-1.14%INTC+2.01%ABBV-0.51%1398.HK-2.09%CSCO+0.92%CVX+1.52%BAC+0.09%ORCL-1.88%COST-0.98%KO-1.05%CAT-0.39%DELL+4.16%HSBA.L-0.77%0005.HK-3.21%UNH-1.58%PG-0.14%LRCX-1.21%AP2d-1.57%AMAT-0.50%NFLX-3.41%GE-1.97%MS-1.82%1816.HK-0.46%3988.HK-2.13%0857.HK+0.60%HD-1.15%PM-1.35%0939.HK-2.83%NZDUSD-0.99%USDJPY+0.87%GBPNZD+0.77%NZDCHF-0.71%USDTHB+0.70%NZDCAD-0.68%CHFJPY+0.67%GBPJPY+0.61%AUDUSD-0.60%EURNZD+0.57%CADJPY+0.56%EURUSD-0.43%EURJPY+0.42%GBPTRY+0.41%AUDNZD+0.40%NZDMXN-0.39%GBPAUD+0.34%PLNJPY+0.33%GBPHKD+0.32%USDCAD+0.31%AUDCHF-0.29%AUDJPY+0.29%USDCHF+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCAD-0.27%USDTRY+0.25%NZDSGD-0.24%GBPUSD-0.23%SGDJPY+0.21%EURAUD+0.18%EURGBP-0.17%AUDDKK-0.16%USDILS+0.16%EURSGD+0.16%USDSGD+0.16%EURSEK+0.16%USDSEK+0.15%EURCAD-0.14%EURCHF-0.12%NZDJPY-0.12%EURCZK+0.11%CHFNOK-0.10%GBPSGD+0.10%GBPZAR-0.10%AUDNOK-0.08%GBPCAD+0.08%USDNOK+0.08%EURNOK+0.07%USDCNH+0.07%USDZAR-0.06%EURZAR-0.05%EURCNH+0.05%USDCOP-0.04%CADCHF-0.04%GBPCHF+0.03%EURPLN+0.03%USDPLN+0.03%CHFSGD-0.03%CHFSEK-0.02%USDHKD+0.02%USDMXN+0.01%EURHKD+0.01%USDDKK-0.01%EURDKK-0.01%AUDSGD0.00%USOIL+1.87%UKOIL+1.20%XNGUSD+0.93%SUGAR-0.88%COFFEE-0.80%W1+0.77%S1+0.61%C1+0.59%HG1+0.52%XPTUSD+0.51%GAGUSD+0.36%XAGUSD+0.36%BTCUSD-2.30%ETHUSD-3.00%USDTUSD-0.03%XRPUSD-1.12%SOLUSD-2.44%TRXUSDT-0.15%ZECUSDT-3.23%DOGEUSD-1.15%XMRUSDT+0.88%LINKUSD-1.80%XLMUSD+2.00%BCHUSDT-0.09%UNIUSD-3.07%LTCUSD-1.65%HBARUSDT+0.70%TONUSD+26.79%SUIUSD-1.69%TAOUSDT-3.21%AAVEUSD-1.00%DOTUSDT-1.91%ICPUSDT-6.96%ONDOUSDT-2.67%WLDUSDT-1.03%ARBUSDT+3.90%ATOMUSDT-1.35%JUPUSDT-3.88%INJUSDT-6.42%STXUSDT-1.97%FETUSDT-3.34%PYTHUSDT-3.63%TIAUSDT-4.18%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-1.70%GRTUSDT-3.39%WIFUSDT-4.27%POLUSDT+0.38%IOTAUSDT-4.18%AXSUSDT-2.99%FARTCOINUSDT-0.77%EOSUSDT-3.12%DYDXUSDT-5.44%ORDIUSDT-1.04%GALAUSDT-0.88%NOTUSDT-0.18%RONINUSDT-4.03%
NK

Nkarta, Inc. (NKTX)

NASDAQ • Healthcare

$2.92
+$0 (+0.3%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$2.92
Previous Close$2.92
Day Range$2.87 - $3.08
Avg. Volume (3M)577.3K
Market Cap$208.9M
52 Week Range
$1.7$3.72
Next EarningsIn 56 daysNov 10, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$117.3M
EPS (TTM)
-$1.57
ROA (TTM)
-34.75%
Current Ratio
7.98

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-15.6%Q1 2026-$0.37
+5.1%Q2 2026-$0.37
-49.9%Q3 2026-$0.54
Next

Nov 10

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -49.9%

Nkarta missed EPS consensus in the second fiscal quarter of 2026, based on preliminary results reported Aug. 10, with EPS of -$0.54 versus the -$0.36 estimate, a -49.9% miss. Gross profit was zero, the company posted an operating loss of about $43.1 million, and net income was a loss of about $40.4 million, down 75.7% from about $23.0 million a year ago. EPS was also down 74.2% from -$0.31 a year earlier, and operating cash flow was negative $24.2 million. Consensus for the next period calls for EPS of -$0.37.

View full earnings history

About Nkarta, Inc.

Nkarta, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector developing cell therapies built from natural killer cells, with work aimed at treating cancer and autoimmune disease. In qualitative terms, it is a clinical-stage biotech, and the company went public in 2020.

Name
Nkarta, Inc.
CEO
Paul J. Hastings
Website
www.nkartatx.com
Industry
Healthcare
Year Founded
2015
Employees
106

Today's Snapshot

AI-generated

Yesterday NKTX finished slightly up at 2.92.

Trading Volume

Below 10d avg (651.1K)

491K

vs S&P 500 Today

Outperforming Market

+0.82%

Updated: September 15, 2026 at 12:12 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
At 2.92, NKTX registers firm bullish internals consistent with a strong-buy rating. Trend strength is confirmed by a high ADX, and multiple momentum measures including CCI and MACD are positive, indicating active upside momentum while RSI remains comfortably above neutral. The price trades above its short-, medium- and long-term moving averages, and on-balance volume is supportive, pointing to constructive participation. Volatility is relatively elevated, which could mean larger intraday swings even as the uptrend persists. Technical takeaway: Strong buy.
All signals
  • EMA (5 indicators)$2.45 - $2.86
    Buy
  • RSI (14)57.73
    Neutral
  • Stochastic %K (14, 3, 3)46.24
    Neutral
  • MACD Level (12, 26)0.12
    Buy

Peers & Related Assets

FATEFate Therapeutics, Inc.
$2.34+1.3%
ALECAlector, Inc.
$2.21+3.3%
FBRXForte Biosciences, Inc.
VORVor Biopharma Inc.
CYBNCybin Inc.
PEPGPepGen Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.